Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827087 | 0.98 | KCNH2 (0.50) | KCNH2POLBNPC1RAB9AMAPT | |
| SCHEMBL2463454 | 0.82 | POLB (0.47) | KCNH2POLBNPC1RAB9AMAPT | |
| N4-Hydroxycytosine SCHEMBL31006505 | 0.76 | — | — | |
| SCHEMBL4412558 | 0.75 | SMN1; SMN2 (0.46) | POLBNPC1RAB9AMAPTKMT2A | |
| SCHEMBL3451050 | 0.71 | — | — | |
| SCHEMBL31685701 | 0.70 | GAA (0.48) | POLBKMT2AGAAKDM4EMEN1 | |
| SCHEMBL13135968 | 0.69 | HSD17B10 (0.42) | POLBMAPTGAAKDM4EHSP90AA1 | |
| Nitric Acid SCHEMBL16448333 | 0.69 | POLB (0.45) | KCNH2POLBNPC1RAB9AMAPT | |
| SCHEMBL1358942 | 0.68 | RXFP1 (0.43) | POLBMAPTKMT2APTK2GAA | |
| SCHEMBL3797719 | 0.67 | KDM4E (0.37) | POLBMAPTKMT2APTK2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-119019837-B | Self-repairing material assembled by nucleobase pairs and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025072862-A9 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137486-A1 | CAP COMPOUNDS AND RNAS COMPRISING THE SAME | HELIX NANOTECHNOLOGIES INC (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025072862-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025042722-A1 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | HELIX NANOTECHNOLOGIES INC (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240420843-A1 | METAEPIGENOMICS-BASED DISEASE DIAGNOSTICS | Universal Diagnostics, S.A. (ES) | 2024-12-19 | — | — | US | disclosed |
| CN-119019837-A | Self-repairing material assembled by nucleobase pairs and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2024-11-26 | — | — | CN | disclosed |
| EP-4413154-A2 | METAEPIGENOMICS-BASED DISEASE DIAGNOSTICS | Micronoma, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118147100-A | N-deoxyribotransferase C1 mutant and application thereof in 2' -deoxyribose transfer | 上海合全药物研发有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-1534286-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113398-A1 | Use of 5-halo or trifluoromethylpyrimidine-2,4-diamine compounds to treat proliferative diseases such as tumorgenic cancers | RIGEL PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005016893-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005013996-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES AS ANTI-PROLIFERATIVE AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| WO-2005012294-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004014382-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | KCNH2 4735/4885POLB 1652/4885NPC1 4203/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | KCNH2 4299/4885POLB 4509/4885NPC1 2094/4885 |
| US-20050113398-A1 | Use of 5-halo or trifluoromethylpyrimidine-2,4-diamine compounds to treat proliferative diseases such as tumorgenic cancers | MKI67, DPYD, VHL | KCNH2 3694/4885POLB 175/4885NPC1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.